Search

Search Constraints

You searched for: Author/Creator Clavert, A.

Search Results

2. IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO‐RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END‐POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK. (June 2017)

3. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. (August 2019)

4. PD‐1 BLOCKADE IN A FRENCH SERIES OF 13 RELAPSED / REFRACTORY NK/T‐CELL LYMPHOMA PATIENTS. (12th June 2019)